Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00326807 |
Recruitment Status :
Completed
First Posted : May 17, 2006
Last Update Posted : May 17, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Concurrent Alcohol Dependence and Pathological Gambling | Drug: Naltrexone | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 50 participants |
Allocation: | Randomized |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling |
Study Start Date : | June 2001 |
Study Completion Date : | June 2004 |

- Gambling Urge Questionnaire
- Obsessive Compulsive Drinking Scale
- Readiness to Change Questionnaire
- Frequency of drinking/gambling
- Amount of drinking/gambling
- Money spent of gambling

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- DSM-IV diagnosis of alcohol abuse and dependence
- Diagnosis of pathological gambling
- Drinking on at least 50% of the days in the preceding month
- Gambling at least weekly in the month prior to assessment
Exclusion Criteria:
- Dependence or abuse of any other psychoactive substances (except for nicotine dependence)
- Concurrent diagnoses of any other psychiatric disorder,
- Serious medical illness
- Laboratory evidence of significant hepatocellular injury
- Use of disulfiramuse and/or opioid-containing medications
- Psychosocial crisis
- Pregnancy
- Inability to read or write English.
- Poor motivation to change alcohol or gambling behavior

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00326807
Canada, Ontario | |
Centre for Addiction and Mental Health | |
Toronto, Ontario, Canada, M5S 2S1 | |
Finland | |
National Public Health Institute | |
Helsinki, Finland, FIN-00101 |
Principal Investigator: | Tony Toneatto, PhD | Centre for Addiction and Mental Health |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00326807 |
Other Study ID Numbers: |
095/2001 |
First Posted: | May 17, 2006 Key Record Dates |
Last Update Posted: | May 17, 2006 |
Last Verified: | May 2006 |
naltrexone alcohol gambling concurrent |
Alcoholism Gambling Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Disruptive, Impulse Control, and Conduct Disorders |
Naltrexone Alcohol Deterrents Narcotic Antagonists Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |